A homogeneous fluorescent live-cell assay for measuring 7-transmembrane receptor activity and agonist functional selectivity through beta-arrestin recruitment.
Seven-transmembrane (7TM) receptors play an essential role in the regulation of a wide variety of physiological processes, making them one of the top target classes for pharmaceuticals. 7TM receptor function is mediated and modulated through 2 primary processes: G-protein and beta-arrestin signaling. Classically, it has been recognized that these 2 processes can interact with one another during 7TM receptor desensitization, but it has more recently been recognized that these 2 processes can also act independently of one another and can activate parallel signaling pathways. As such, the methods used to interrogate 7TM receptor signaling, both from a biological and a pharmaceutical perspective, may need to be reevaluated and the question of whether functionally selective compounds (compounds that selectively activate one pathway over another) can be rationally developed must be raised. Although numerous high-throughput screening (HTS) compatible assays exist for studying second messengers arising from G-protein signaling, far fewer HTS compatible assays exist for studying beta-arrestin recruitment. The authors report on the Tango 7TM receptor assay technology, a high-throughput homogeneous assay method for monitoring beta-arrestin recruitment that uses a live-cell fluorescent readout. This assay format is broadly applicable to 7TM receptors, independent of G-protein coupling and, as such, has been used to produce assays for over 70 7TM receptor targets. The authors also show how flow cytometry can be used to select clones with desired pharmacological profiles and how an inducible expression system can increase the assay window for targets with high levels of constitutive activity. Finally, they demonstrate how the Tango system can be used in parallel with assays aimed at second-messenger signaling to enable functional selectivity studies.
Hanson
Bonnie J
BJ
Invitrogen Corporation, Madison, Wisconsin 53719, USA. bonnie.hanson@invitrogen.com
Wetter
Justin
J
Bercher
Mark R
MR
Kopp
Leisha
L
Fuerstenau-Sharp
Maya
M
Vedvik
Kevin L
KL
Zielinski
Thomas
T
Doucette
Chris
C
Whitney
Pamela J
PJ
Revankar
Chetana
C
D019390:Arrestins / Q000819:agonists*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002999:Clone Cells; D004318:Doxycycline / Q000494:pharmacology; D005434:Flow Cytometry; D005453:Fluorescence; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans; D011956:Receptors, Cell Surface / Q000378:metabolism*; D013752:Tetracycline / Q000494:pharmacology; D000071557:beta-Arrestins; D001618:beta-Lactamases / Q000378:metabolism
D019390:Arrestins; D011956:Receptors, Cell Surface; D000071557:beta-Arrestins; D001618:beta-Lactamases; D013752:Tetracycline; D004318:Doxycycline